Lurbinectedin is a drug that is being studied for its potential use in the treatment of various types of cancer. According to the sources provided, there is no clear answer as to when lurbinectedin will be available for patients.
The drug is currently in clinical trials, which are being conducted to determine its safety and effectiveness in treating different types of cancer. The trials are ongoing, and it is unclear when they will be completed. Once the trials are completed, the drug will need to be reviewed by regulatory agencies, such as the FDA, before it can be approved for use in patients.
One source [1] notes that the patent for lurbinectedin is set to expire in 2036, which suggests that the drug is still in the early stages of development and may not be available for several years.
Another source [2] provides more information about the ongoing clinical trials of lurbinectedin. According to this source, the drug is being studied for its potential use in the treatment of small cell lung cancer, ovarian cancer, and other types of solid tumors. The trials are still ongoing, and it is unclear when they will be completed.
A third source [3] provides some insight into the potential benefits of lurbinectedin in the treatment of cancer. According to this source, the drug has shown promise in preclinical studies and early clinical trials. It has been shown to have antitumor activity and to be well-tolerated by patients.
In conclusion, while lurbinectedin shows promise as a potential treatment for various types of cancer, it is still in the early stages of development. Clinical trials are ongoing, and it is unclear when they will be completed. Once the trials are completed, the drug will need to be reviewed by regulatory agencies before it can be approved for use in patients. Therefore, it is not possible to predict when lurbinectedin will be available for patients at this time.
Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.cancer.gov/about-cancer/treatment/drugs/lurbinectedin
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331752/